Intra-Cellular Therapies Inc (ITCI):企業の財務・戦略的SWOT分析

◆英語タイトル:Intra-Cellular Therapies Inc (ITCI) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C14918
◆発行会社(調査会社):GlobalData
◆発行日:2019年3月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD300 ⇒換算¥33,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD600 ⇒換算¥66,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥99,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Intra-Cellular Therapies Inc (ITI) is a novel drug manufacturer. The company offers product platform such as ITCI Pipeline that includes lumateperone, ITI-007 platform, PDE inhibitor platform and drug discovery platform. The company’s lead product candidate ITI-007-lumateperone is to treat schizophrenia, behavioural disturbances in dementia, sleep and behavioural disturbances associated with autism spectrum disorder, other mood disorders, sleep disturbances associated with neurologic and psychiatric disorders, and others. Its CNSProfile technology monitors the phosphoprotein changes and generates a unique molecular signature for drug compounds. The company utilizes phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of central nervous system and other disorders. ITI is headquartered in New York, the US.

Intra-Cellular Therapies Inc Key Recent Developments

Feb 27,2019: Intra-Cellular therapies reports fourth quarter and full-year 2018 financial results and provides corporate update
Dec 11,2018: Intra-Cellular Therapies Announces Favorable Results From Long-Term Open-Label Safety Switching Study With Lumateperone in Patients with Schizophrenia at the 57th Annual Meeting of the American College of Neuropsychopharmacology
Nov 07,2018: Intra-Cellular Therapies provides corporate update and reports third quarter 2018 financial results
Oct 16,2018: Intra-Cellular Therapies appoints Mark Neumann as executive vice president, chief commercial officer
Sep 25,2018: Intra-Cellular Therapies names Michael Olchaskey as Senior Vice President, Head of Regulatory Affairs

This comprehensive SWOT profile of Intra-Cellular Therapies Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Intra-Cellular Therapies Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Intra-Cellular Therapies Inc – Key Information
Intra-Cellular Therapies Inc – Overview
Intra-Cellular Therapies Inc – Key Employees
Intra-Cellular Therapies Inc – Key Employee Biographies
Intra-Cellular Therapies Inc – Key Operational Heads
Intra-Cellular Therapies Inc – Major Products and Services
Intra-Cellular Therapies Inc – History
Intra-Cellular Therapies Inc – Company Statement
Intra-Cellular Therapies Inc – Locations And Subsidiaries
Intra-Cellular Therapies Inc – Key Manufacturing facilities
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Intra-Cellular Therapies Inc – Business Description
Intra-Cellular Therapies Inc – Corporate Strategy
Intra-Cellular Therapies Inc – SWOT Analysis
SWOT Analysis – Overview
Intra-Cellular Therapies Inc – Strengths
Intra-Cellular Therapies Inc – Weaknesses
Intra-Cellular Therapies Inc – Opportunities
Intra-Cellular Therapies Inc – Threats
Intra-Cellular Therapies Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Intra-Cellular Therapies Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Intra-Cellular Therapies Inc, Key Information
Intra-Cellular Therapies Inc, Key Ratios
Intra-Cellular Therapies Inc, Share Data
Intra-Cellular Therapies Inc, Major Products and Services
Intra-Cellular Therapies Inc, History
Intra-Cellular Therapies Inc, Key Employees
Intra-Cellular Therapies Inc, Key Employee Biographies
Intra-Cellular Therapies Inc, Key Operational Heads
Intra-Cellular Therapies Inc, Other Locations
Intra-Cellular Therapies Inc, Subsidiaries
Intra-Cellular Therapies Inc, Key Manufacturing facilities
Intra-Cellular Therapies Inc, Key Competitors
Intra-Cellular Therapies Inc, SWOT Analysis
Intra-Cellular Therapies Inc, Ratios based on current share price
Intra-Cellular Therapies Inc, Annual Ratios
Intra-Cellular Therapies Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Intra-Cellular Therapies Inc, Performance Chart
Intra-Cellular Therapies Inc, Ratio Charts

★海外企業調査レポート[Intra-Cellular Therapies Inc (ITCI):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • NeoGenomics Inc (NEO):企業の財務・戦略的SWOT分析
    Summary NeoGenomics Inc (NeoGenomics) is a cancer diagnostics and pharma services company that offers diagnostic, prognostic and predictive testing services. The company offers testing services with various technologies such as cytogenetics, fluorescence in-situ hybridization, flow cytometry, immuno …
  • Moog Inc.:企業の戦略・SWOT・財務情報
    Moog Inc. - Strategy, SWOT and Corporate Finance Report Summary Moog Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Enercon GmbH:企業の戦略的SWOT分析
    Enercon GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Aquinox Pharmaceuticals Inc (AQXP):企業の財務・戦略的SWOT分析
    Summary Aquinox Pharmaceuticals Inc (Aquinox) is a pharmaceutical company that discovers and develops novel drug candidates for the treatment of inflammation, inflammatory pain, and blood cancers. The company's lead drug candidate include AQX-1125, is a small molecular activator of SHIP1 which is a …
  • Edan Instruments Inc (300206):企業の財務・戦略的SWOT分析
    Summary Edan Instruments Inc (Edan Instruments) is a medical equipment provider that offers ECG equipments. The company offers diagnostic ECG, obstetrics and gynaecology monitoring systems; patient monitoring devices, ultrasound imaging, point-of-care testing, in-vitro diagnostics and veterinary equ …
  • Seres Therapeutics Inc (MCRB):企業の財務・戦略的SWOT分析
    Summary Seres Therapeutics Inc (Seres), is a microbiome therapeutics platform company that develops a novel class of biological drugs. The company creates a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. The company’ …
  • ZF Friedrichshafen AG:企業の戦略的SWOT分析
    ZF Friedrichshafen AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • ACEA Biosciences Inc-医療機器分野:企業M&A・提携分析
    Summary ACEA Biosciences Inc (ACEA) is a biotechnology company that concentrates on the development and commercialization of innovative cell analysis instrumentation for life science research and clinical diagnostics. The company's products include impedance-based, label-free, and real-time cell ana …
  • Cti Engineering Co Ltd:企業の戦略・SWOT・財務分析
    Cti Engineering Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Cti Engineering Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • First Light Biosciences Inc:企業の製品パイプライン分析2018
    Summary First Light Biosciences Inc (FLB) is a medical device company that develops and manufactures automated medical diagnostic products for the detection of healthcare associated infections. The company’s product includes multipath analyzer system. Its multipath analyzer system detects resistant …
  • Schindler Holding Ltd.:戦略・SWOT・企業財務分析
    Schindler Holding Ltd. - Strategy, SWOT and Corporate Finance Report Summary Schindler Holding Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Welltec AS:石油・ガス:M&Aディール及び事業提携情報
    Summary Welltec AS (Welltec) is an oil and gas service provider that develops and offers well technologies and solutions for the oil and gas industries. The company's solutions include wireline services, milling solutions, robotic well solutions, conveyance solutions, clean-out solutions, and mechan …
  • TransAlta Corporation:企業の戦略・SWOT・財務分析
    TransAlta Corporation - Strategy, SWOT and Corporate Finance Report Summary TransAlta Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Fred Hutchinson Cancer Research Center:企業のM&A・事業提携・投資動向
    Fred Hutchinson Cancer Research Center - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Fred Hutchinson Cancer Research Center Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed repo …
  • Fraser & Neave Holdings Bhd:戦略・SWOT・企業財務分析
    Fraser & Neave Holdings Bhd - Strategy, SWOT and Corporate Finance Report Summary Fraser & Neave Holdings Bhd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • GAIN Capital Holdings, Inc.:企業のM&A・事業提携・投資動向
    GAIN Capital Holdings, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's GAIN Capital Holdings, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Department of Defense Education Activity:企業の戦略的SWOT分析
    Department of Defense Education Activity - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Finnair Oyj:戦略・SWOT・企業財務分析
    Finnair Oyj - Strategy, SWOT and Corporate Finance Report Summary Finnair Oyj - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • First Bank Of Nigeria Ltd
    First Bank Of Nigeria Ltd - Strategy, SWOT and Corporate Finance Report Summary First Bank Of Nigeria Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • ARUP Laboratories:医療機器:M&Aディール及び事業提携情報
    Summary ARUP Laboratories (ARUP) is a clinical and anatomical pathology reference laboratory. It is a nonprofit enterprise of the University of Utah and its Department of Pathology. The company provides several tests and test combinations in the fields of anatomic pathology, genetics, pain managemen …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆